OLIPASS Corporation
OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD… Read more
Market Cap & Net Worth: OLIPASS Corporation (244460)
OLIPASS Corporation (KQ:244460) has a market capitalization of $6.10 Million (₩8.94 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #33253 globally and #2116 in its home market, demonstrating a -53.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OLIPASS Corporation's stock price ₩1651.00 by its total outstanding shares 5412210 (5.41 Million).
OLIPASS Corporation Market Cap History: 2019 to 2025
OLIPASS Corporation's market capitalization history from 2019 to 2025. Data shows change from $579.10 Million to $6.10 Million (-56.39% CAGR).
Index Memberships
OLIPASS Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.00% | #1174 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.00% | #1174 of 1384 |
Weight: OLIPASS Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OLIPASS Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OLIPASS Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
OLIPASS Corporation's market cap is 0.03 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $579.10 Million | $1.71 Billion | -$45.64 Billion | 0.34x | N/A |
| 2020 | $681.36 Million | $2.86 Billion | -$24.18 Billion | 0.24x | N/A |
| 2021 | $339.69 Million | $851.78 Million | -$25.13 Billion | 0.40x | N/A |
| 2022 | $225.11 Million | $2.30 Billion | -$24.17 Billion | 0.10x | N/A |
| 2023 | $28.61 Million | $5.68 Billion | -$12.54 Billion | 0.01x | N/A |
| 2024 | $19.18 Million | $756.03 Million | -$5.32 Billion | 0.03x | N/A |
Competitor Companies of 244460 by Market Capitalization
Companies near OLIPASS Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to OLIPASS Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
OLIPASS Corporation Historical Marketcap From 2019 to 2025
Between 2019 and today, OLIPASS Corporation's market cap moved from $579.10 Million to $ 6.10 Million, with a yearly change of -56.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩6.10 Million | -68.19% |
| 2024 | ₩19.18 Million | -32.95% |
| 2023 | ₩28.61 Million | -87.29% |
| 2022 | ₩225.11 Million | -33.73% |
| 2021 | ₩339.69 Million | -50.14% |
| 2020 | ₩681.36 Million | +17.66% |
| 2019 | ₩579.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of OLIPASS Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.10 Million USD |
| MoneyControl | $6.10 Million USD |
| MarketWatch | $6.10 Million USD |
| marketcap.company | $6.10 Million USD |
| Reuters | $6.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.